Alirocumab as add-on to atorvastatin versus other lipid treatment strategies: ODYSSEY OPTIONS I randomized trial

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 8, 2015, Pages 3140-3148

  Bays, Harold ^a   Gaudet, Daniel ^b   Weiss, Robert ^c   Ruiz, Juan Lima ^d   Watts, Gerald F ^e   Gouni Berthold, Ioanna ^f   Robinson, Jennifer ^g   Zhao, Jian ^h   Hanotin, Corinne ⁱ   Donahue, Stephen ^h  

^a LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER   (United States)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c Maine Research Associates   (United States)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^f UNIVERSITY OF COLOGNE   (Germany)

^g UNIVERSITY OF IOWA   (United States)

^h REGENERON PHARMACEUTICALS INC   (United States)

ⁱ SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALIROCUMAB; APOLIPOPROTEIN B; ATORVASTATIN; CREATINE KINASE; EZETIMIBE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; ANTIBODY; AZETIDINE DERIVATIVE; HEPTANOIC ACID DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; MONOCLONAL ANTIBODY; PYRROLE DERIVATIVE;

ADD ON THERAPY; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLERGIC RHINITIS; ANTIBODY RESPONSE; ARTICLE; BACKACHE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENZYME BLOOD LEVEL; FEMALE; HEART ARREST; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; IMMUNOGENICITY; INJECTION SITE REACTION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NAUSEA; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PARALLEL DESIGN; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; PULMONARY ASPIRATION; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY DISTRESS SYNDROME; RHINOPHARYNGITIS; RISK ASSESSMENT; RISK REDUCTION; SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; URTICARIA; BLOOD; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; DRUG COMBINATION; IMMUNOLOGY; TREATMENT OUTCOME;

AGED; ANTIBODIES; ANTIBODIES, MONOCLONAL; ANTICHOLESTEREMIC AGENTS; ATORVASTATIN CALCIUM; AZETIDINES; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; DRUG THERAPY, COMBINATION; EZETIMIBE; FEMALE; HEPTANOIC ACIDS; HUMANS; MALE; MIDDLE AGED; PYRROLES; TREATMENT OUTCOME;

EID: 84939207026     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2015-1520     Document Type: Article

References (24)

1. Hess G, Chang CL, Chung K. Lipid attainment among patients newly treated with lipid-altering drugs. Curr Med Res Opin. 2014;30:1743-1756.
2. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet. 2010;376:1670-1681.
3. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387-2397.
4. Bays HE, Goldberg RB. The 'forgotten' bile acid sequestrants: is now a good time to remember? Am J Ther. 2007;14:567-580.
5. Nicholls SJ, Brandrup-Wognsen G, Palmer M, Barter PJ. Meta-analysis of comparative efficacy of increasing dose of atorvastatin versus rosuvastatin versus simvastatin on lowering levels of atherogenic lipids (from VOYAGER). Am J Cardiol. 2010;105:69-76.
6. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63:2889-2934.
7. McKenney JM, Koren MJ, Kereiakes DJ, Hanotin C, Ferrand AC, Stein EA. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol. 2012;59:2344-2353.
8. Roth EM, McKenney JM, Hanotin C, Asset G, Stein EA. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med. 2012;367:1891-1900.
9. Stein EA, Gipe D, Bergeron J, et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet. 2012;380:29-36.
10. Roth EM, Taskinen MR, Ginsberg HN, et al. Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized phase 3 trial. Int J Cardiol. 2014;176:55-61.
11. Bays HE, Davidson MH, Massaad R, et al. Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up-titration of rosuvastatin in patients with hypercholesterolemia (the ACTE Study). Am J Cardiol. 2011;108:523-530.
12. Bays HE, Averna M, Majul C, et al. Efficacy and safety of ezetimibe added to atorvastatin versus atorvastatin uptitration or switching to rosuvastatin in patients with primary hypercholesterolemia. Am J Cardiol. 2013;112:1885-1895.
13. Robinson JG, Colhoun HM, Bays HE, et al. Efficacy and safety of alirocumab as add-on therapy in high-cardiovascular-risk patients with hypercholesterolemia not adequately controlled with atorvastatin (20 or 40 mg) or rosuvastatin (10 or 20 mg): design and rationale of the ODYSSEY OPTIONS Studies. Clin Cardiol. 2014;37:597-604.
14. Reiner Z, Catapano AL, De Backer G, et al. ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32:1769-1818.
15. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
16. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-3421.
17. Expert Dyslipidemia Panel of the International Atherosclerosis Society Panel members. An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia - full report. J Clin Lipidol. 2014;8:29-60.
18. Anderson TJ, Gregoire J, Hegele RA, et al. 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol. 2013;29:151-167.
19. Bays HE, Jones PH, Brown WV, Jacobson TA. National Lipid Association annual summary of clinical lipidology 2015. J Clin Lipidol. 2014;8:S1-S36.
20. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol. 2004;44:720-732.
21. Jacobson TA, Ito MK, Maki KC, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 - executive summary. J Clin Lipidol. 2014;8:473-488.
22. Teramoto T, Sasaki J, Ishibashi S, et al. Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan - 2012 version. J Atheroscler Thromb. 2013;20:517-523.
23. Schwartz GG, Bessac L, Berdan LG, et al. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY Outcomes trial. Am Heart J. 2014;168:682-689.
24. Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med. 2014;370:1809-1819.